Alkemi Growth Capital

Founded in 2016, Kli Capital is a New York-based investment firm that specializes in early-stage venture capital investments. We look for promising founders and startups in the consumer products and services, financial services, healthcare, materials and resources, and information technology sectors. Kli Capital has invested in 79+ companies across multiple continents. Check out our portfolio. Please see a recent TechCrunch article on our progress here. Kli Capital has always focused on investing in ambitious entrepreneurs, and now we are looking for an ambitious Associate to join our team.

Muse Capital is an early stage venture fund investing in consumer tech, with a focus on large underserved markets poised for disruption. They focus on investing in products, services and solutions to meet the needs of tomorrow’s increasingly diverse society across how we care (women’s health, digital health, and childcare), how we live (wellness and sustainability), and how we play (gaming, entertainment, web3, and sports tech). Muse Capital’s expertise is sourcing and executing on business development opportunities for their entrepreneurs, leveraging the partners 20+ years of accelerating and operating businesses in both private and public sectors, with their global network of decision makers across F500's, entertainment, sports teams/owners, global investors, and world class tech entrepreneurs. Given their highly strategic value add, they are able to access oversubscribed deals and invest before or alongside some of the top funds in the valley including Andreessen Horowitz, Google Ventures, Forerunner, and Lightspeed to name just a few. Muse Capital’s current fund is a $45m platform dedicated to doubling down on their established track record across the consumer space, and a knack for spotting super-trends and talent early on. Their portfolio of 40+ investments includes Clarity Money (sold to Goldman Sachs), Mahmee (telehealth for new mothers, series A lead by Goldman Sachs), Midi (disrupting the $50B menopause space), Kinside (digitizing the $150B childcare industry), and Beekeeper’s Naturals (replacing the modern medicine cabinet with natural products). The team has also gained exclusive access for their strategic LPs to direct investments into prestigious later stage deals including Robinhood and Byju’s. As a female lead team of conscious capitalists, Muse Capital is a staunch advocate for diversity as better business, and proud to have a portfolio which is 50% minority/female.

Natural inclination towards Deeptech, Health and Behaviour Changes in Consumers' habits. We offer our investments direct and rapid access to decision-makers in the sectors they aim at transforming. Try us, also happy to coinvest.

We invest in visionary changemakers and disruptive technologies that unlock the potential of innovation and uplift humanity. Capital for a better world Elevation Capital is an early-stage venture fund that invests in globally-impactful companies united by a common vision of humanity as the highest purpose. For over 15 years, we have been helping build successful companies that can both make a profit – and make a difference in society. Our investment strategy is guided by the core principle of shared value – the Win-Win – the conscious belief that a company can deliver both a positive financial return and a sustainable social impact. We believe in the transformational power of disruptive technologies, and look for visionary leaders who can develop and unlock innovative applications for positive change both in business and the world at large. At Elevation capital, we invest in bold ideas that chart the course for a brighter future. Visionary Companies, Courageous Teams We look for courageous teams who want to redefine the future, transform the business environment, and make the world a better place. We focus primarily on seed-stage angel funding ($10k-$100k) while also selectively evaluating exponential growth capital ($100k-$2m) opportunities. We also partner with others to invest in visionary entrepreneurs, game-changing innovations, and disruptive technologies that can bring real improvements to the overall health and wellness of our lives. Our investments to date, either directly or indirectly with our partners, have spanned over 30 companies and include health and wellness, biotech, consumer packaged goods, financial services, real estate, housing solutions, hospitality, and technology. Giving Back At Elevation Capital, we are committed to giving back to our communities. Like our venture capital fund, our approach to corporate giving focuses on organizations and charities, regardless of size, that make a tangible and sustainable impact on the environment and communities in which we live. Over the past year, we have provided support to a number of organizations and charities including Foundations for Social Change, Whole Way House, Food Bank Canada, Take a Hike Foundation, Environmental Youth Alliance, and Folds of Honor.

Our approach keeps founders at the heart of everything we do. We areConviction-led: We value independent decision-making and lead all our investments. Long-term partners: We stay fully committed to founders' vision, no matter how long it takes. Sector specialists: We each focus on specific sectors to build a deep, informed point of view that fuels our investment strategy and portfolio support. Transparent: We keep founders in the loop and prioritize honest communication, making us partners they never have to second-guess. Engaged: We believe in staying actively involved through meaningful board participation and functional support. Our journey started like many other startups – in a Bengaluru basement 2016 When we set out to raise our first fund, the Indian VC landscape was shaky at best. Investors were cautious, several foreign VC majors had left the ecosystem, and successful exits were hard to come by. Amidst skepticism about the Indian market, we defiantly believed that the "golden decade" of Indian technology was upon us. We saw an opportunity for VC 2.0 in India – one that was stage-focused, expertise-driven, and committed to prioritizing real growth alongside valuations. Undeterred by a tough fundraising climate, we knocked on 1,200 doors to raise Stellaris’ first fund. These early struggles shaped Stellaris’ culture, allowing us to fully resonate with the fundraising challenges faced by early-stage entrepreneurs. 2017 We launched our first fund of $90 million. From the outset, we established a principle of having specialists on our team, enabling us to tap into deep sector knowledge, spot promising opportunities, and provide tailored support to the companies we backed. Out of our 19 investments in our first fund, 9 surpassed a valuation of $100 million, with several others on track to achieve this milestone. 2021 We closed our second fund of $225M and backed 25 companies, many of which are poised to become the leaders of tomorrow. We also had our first significant exit in the portfolio when 6Sense, a US SaaS company, acquired Slintel, in which Stellaris was the first institutional investor. 2023 Our portfolio company, Mamaearth, which we backed at the Series A stage in 2018, successfully completed its IPO. 2024 We launched our third fund of $300M and are now managing over $600M in assets. We're ready to support the next wave of innovative businesses with the same grit and determination that brought us here.

We are inspired by a vision for the future in which data, computing, networks, and other digital and deep technologies deliver meaningful outcomes and insight for improving health and the provision of care. We invest in both solutions intended for use in the diagnosis or cure of disease and solutions designed to help healthcare organizations - be them hospitals, biopharmas, insurers, etc. - be better at what they do. We see our sweet spot at seeding founders who are marrying in-depth understanding of the complex network of healthcare system participants with meaningful engineering innovation, advanced data science, and information technology-enabled products and services. We look for and invest in founders determined to effectively and efficiently serve these participants on the european continent, where we are based, and internationally.​ In our investment criteria and process, we are informed by a Stanford-born methodology of health technology innovation known as Biodesign. Since 2001, Biodesign has proven to de-risk the process of new venture creation by applying a need-driven and value-based approach to reinventing healthcare with the help of technology. To learn more about the methodology, head to The Student Guide to Biodesign, developed by a team of Stanford instructors and students who are passionate about education and making high-quality learning materials available and accessible to all.​ We invest in european companies as well as in selected non-european companies with ties to europe. Wherever they are, our goal is to help founders ready their companies to raise series A capital, and to access international markets. To learn more about our process, click here.